CompletedPhase 4NCT05911906

An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Derby
Principal Investigator
Victoria Allgar, PhD
Pen CTU
Intervention
Remdesivir(drug)
Enrollment
73 target
Eligibility
18 years · All sexes
Timeline
20242025

Study locations (4)

Collaborators

University of Exeter · University of Plymouth · University Hospitals of Derby and Burton NHS Foundation Trust · Aston University · Royal Devon and Exeter NHS Foundation Trust

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05911906 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials